Exemestane, marketed under the pharmaceutical brand name Aromasin, is a third generation steroidal aromatase inhibitor with FDA approval for breast cancer treatment and the only steroidal aromatase inhibitor among the third generation AI compounds, a structural distinction that produces a fundamentally different mechanism of action from the non steroidal aromatase inhibitors Anastrozole and Letrozole. This formulation delivers 25mg per tablet in a 30 count format, consistent with the concentration most commonly referenced in aromatase inhibition and estrogen biosynthesis research literature.

Exemestane’s steroidal structure is the defining pharmacological characteristic that differentiates it from Anastrozole within CSD’s aromatase inhibitor range. Anastrozole is a non steroidal competitive and reversible aromatase inhibitor. Tt competes with androgens for CYP19A1 enzyme binding but does not permanently alter the enzyme. Exemestane is a steroidal mechanism based irreversible aromatase inactivator. Its androstenedione derived structure allows it to bind the aromatase active site and form a permanent covalent bond with the enzyme, irreversibly inactivating it. This irreversible mechanism produces aromatase suppression that persists until new enzyme is synthesized; a pharmacological distinction from reversible inhibitors that has generated specific comparative research into the clinical and biological differences between reversible competitive inhibition and irreversible mechanism based inactivation across aromatase enzyme activity studies.

Exemestane’s steroidal androstenedione derived structure also produces a secondary androgenic metabolitel 17-hydroexemestane; which carries weak androgenic activity through androgen receptor binding. This androgenic metabolite activity is unique among aromatase inhibitors and absent from non steroidal alternatives like Anastrozole, generating specific research interest in the differential effects of steroidal versus non steroidal aromatase inhibition on androgen receptor activity, bone metabolism, and lipid profiles in comparative AI research. CSD stocks both Exemestane and Anastrozole. Allows researchers access to both irreversible steroidal and reversible non steroidal aromatase inhibition mechanisms from a single verified Canadian supplier for complete comparative AI research coverage.

Every batch of CSD’s Exemestane is third party lab tested for concentration accuracy and purity before being made available, with COA documentation available on request. Canada Steroid Depot has supplied Canadian customers with consistently verified, accurately dosed research compounds for years, and our estrogen management range: Anastrozole, Exemestane, Tamoxifen, Clomiphene, Enclomiphene, and Raloxifene. Products cover aromatase inhibition and SERM estrogen regulation research from a single verified Canadian supplier. All orders ship discreetly across Canada in plain, unmarked packaging with no identifying information on the exterior.

Store in a cool, dry place away from direct light and heat. Intended for research purposes only.

Commonly researched alongside Anastrozole in comparative steroidal versus non steroidal aromatase inhibitor studies. Browse CSD’s full PCT and hormone research range for complete sourcing.